Want to see GB:FDBK full AI Analyst Report?
Top Page
Feedback
(LSE:FDBK)
Select Model
Select Model
Rating:44Neutral
Price Target:
6.50 p
▼(-5.11% Downside)
Action:Reiterated
Date:05/20/26
The score is held down primarily by weak financial performance (shrinking revenue, worsening losses, and ongoing cash burn) and bearish technicals (below major moving averages with negative MACD). A debt-free balance sheet and high gross margin provide some support, but not enough to offset profitability and cash-flow risks.
Positive Factors
Debt-free balance sheet
Feedback's zero-debt balance sheet meaningfully reduces refinancing and interest-rate risk. For a small digital-health software provider, no financial leverage preserves strategic flexibility and extends runway, allowing management to pursue restructuring or growth without fixed financing obligations.
Negative Factors
Sharp revenue decline
A sustained ~25-30% revenue decline materially reduces the addressable recurring base for a SaaS business. Lower recurring sales hinder absorption of fixed operating costs, slow path to profitability, and make it difficult to leverage the company's high gross margins into improved operating results without revenue stabilization.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Feedback's zero-debt balance sheet meaningfully reduces refinancing and interest-rate risk. For a small digital-health software provider, no financial leverage preserves strategic flexibility and extends runway, allowing management to pursue restructuring or growth without fixed financing obligations.
Read all positive factors
Feedback (FDBK) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£3.00M
Dividend YieldN/A
Average Volume (3M)76.45K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue Growth-28.82%
EPS Growth31.59%
CountryUK
Employees29
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.16
Shares Outstanding43,814,777
10 Day Avg. Volume152,066
30 Day Avg. Volume76,453
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.67
Price to Sales (P/S)4.70
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.26
Revenue Forecast (FY)£810.00K
Feedback Business Overview & Revenue Model
Company Description
Feedback plc is a medical technology company, headquartered in London, UK, and established in 1958, that supplies specialized software and systems to individuals and organizations working within the medical imaging sector. Their product portfolio ...
How the Company Makes Money
Feedback plc generates revenue primarily by selling and licensing its digital health software to healthcare providers and related organizations. Its core revenue stream is typically recurring software income (e.g., subscription/SaaS or term licenc...
Feedback Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 849.62K | 885.62K | 1.18M | 1.02M | 588.58K | 287.42K |
| Gross Profit | 535.65K | 778.65K | 1.10M | 131.39K | -63.68K | 213.64K |
| EBITDA | -3.91M | -4.19M | -2.73M | -2.61M | -1.96M | -2.01M |
| Net Income | -7.18M | -7.32M | -3.30M | -2.92M | -2.12M | -1.62M |
Balance Sheet | ||||||
| Total Assets | 4.86M | 6.75M | 8.34M | 11.72M | 14.30M | 5.82M |
| Cash, Cash Equivalents and Short-Term Investments | 3.82M | 5.95M | 3.88M | 7.32M | 10.31M | 2.22M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 400.00K | 589.02K | 694.18K | 855.45K | 594.13K | 552.83K |
| Stockholders Equity | 4.46M | 6.16M | 7.64M | 10.87M | 13.71M | 5.27M |
Cash Flow | ||||||
| Free Cash Flow | -3.30M | -2.83M | -2.14M | -2.99M | -2.41M | -3.47M |
| Operating Cash Flow | -3.29M | -2.82M | -2.22M | -1.74M | -1.25M | -2.03M |
| Investing Cash Flow | -725.81K | -716.00K | -1.22M | -1.24M | -1.15M | -1.44M |
| Financing Cash Flow | 496.49K | 5.61M | 0.00 | -830.00 | 10.49M | 4.96M |
Feedback Technical Analysis
Neutral
6.85
Price Trends
6.50
Positive
7.87
Negative
9.44
Negative
Market Momentum
0.12
Negative
77.36
Negative
85.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FDBK, the sentiment is Neutral. The current price of 6.85 is above the 20-day moving average (MA) of 6.34, above the 50-day MA of 6.50, and below the 200-day MA of 9.44, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 77.36 is Negative, neither overbought nor oversold. The STOCH value of 85.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:FDBK.
Feedback Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £58.97M | 25.86 | 8.84% | ― | -5.18% | -66.95% | |
56 Neutral | £16.97M | -3.95 | -16.18% | ― | 13.04% | 15.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £21.27M | -1.28 | -1044.57% | ― | 65.60% | 74.84% | |
44 Neutral | £3.00M | -0.43 | -135.17% | ― | -28.82% | 31.59% | |
44 Neutral | £16.73M | -8.09 | -62.89% | ― | -9.11% | 18.91% | |
42 Neutral | £15.79M | -0.30 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:FDBK
Feedback
6.85
-6.40
-48.30%
GB:COG
Cambridge Cognition Holdings
31.00
-1.50
-4.62%
GB:GDR
Genedrive
1.40
0.81
136.09%
GB:IXI
IXICO plc
7.75
-4.50
-36.73%
GB:OBD
Oxford BioDynamics
0.12
-0.36
-75.00%
GB:KOO
Kooth
195.00
37.50
23.81%
Feedback Corporate Events
Business Operations and StrategyFinancial Disclosures
Feedback plc holds revenue steady as Bleepa gains traction with NHS
Positive
Jul 14, 2026
Feedback plc reported flat revenue of about £0.8m for the year to 31 May 2026 but said its EBITDA loss will be lower than expected thanks to tight cost controls and cash management. Year-end cash of £2.7m came in ahead of forecasts, givi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.